<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03900104</url>
  </required_header>
  <id_info>
    <org_study_id>CEIN</org_study_id>
    <nct_id>NCT03900104</nct_id>
  </id_info>
  <brief_title>Cervical and Endometrial Injection for Sentinel Lymph Node Detection in Endometrial Cancer</brief_title>
  <official_title>Cervical and Endometrial Injection for Sentinel Lymph Node Detection in Endometrial Cancer: A Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kocaeli University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kocaeli University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators think that trans-cervical endometrial tracer injection will cause more
      paraaortic sentinel lymph node detection. Also, this application is easy, cost-effective and
      safer than hysteroscopic method. Transtubal tumor spearing will not occur with this method.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endometrial tracer injection will be performed by cervical or transcervical endometrial
      methods. Pelvic and para-aortic sentinel lymph node detection capacity will be assessed in
      this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Actual">January 15, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detected pelvic and paraaortic sentinel lymph node numbers</measure>
    <time_frame>Postoperative 30 days</time_frame>
    <description>Detected pelvic and paraaortic sentinel lymph node numbers in pathological examination (Ultrastaging)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numbers adverse events</measure>
    <time_frame>Postoperative 90 days</time_frame>
    <description>Number of adverse events associated with the surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Endometrial Cancer</condition>
  <condition>Sentinel Lymph Node</condition>
  <arm_group>
    <arm_group_label>Transcervical endometrial injection arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tracer injection performed by a transcervical catheter in endometrial cancer patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervical injection arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tracer injection was administered via the cervical route in endometrial cancer patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles</intervention_name>
    <description>Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery. Injection performed with a trans-cervical catheter</description>
    <arm_group_label>Transcervical endometrial injection arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cervical injection of technetium 99 m-labeled human albumin colloid particles</intervention_name>
    <description>Cervical injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery.</description>
    <arm_group_label>Cervical injection arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Endometrial Cancer Patients

          -  Suitable patients for surgical staging

        Exclusion Criteria:

          -  Patients who cannot undergo cervical or transcervical endometrial injection

          -  Pathology did not confirm endometrial cancer

          -  Sarcoma of the uterine corpus

          -  If a 90-day follow-up was not feasible
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Şener Gezer, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kocaeli University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kocaeli University</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Solima E, Martinelli F, Ditto A, Maccauro M, Carcangiu M, Mariani L, Kusamura S, Fontanelli R, Grijuela B, Raspagliesi F. Diagnostic accuracy of sentinel node in endometrial cancer by using hysteroscopic injection of radiolabeled tracer. Gynecol Oncol. 2012 Sep;126(3):419-23. doi: 10.1016/j.ygyno.2012.05.025. Epub 2012 May 30.</citation>
    <PMID>22659192</PMID>
  </reference>
  <reference>
    <citation>Niikura H, Kaiho-Sakuma M, Tokunaga H, Toyoshima M, Utsunomiya H, Nagase S, Takano T, Watanabe M, Ito K, Yaegashi N. Tracer injection sites and combinations for sentinel lymph node detection in patients with endometrial cancer. Gynecol Oncol. 2013 Nov;131(2):299-303. doi: 10.1016/j.ygyno.2013.08.018. Epub 2013 Aug 27.</citation>
    <PMID>23988415</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 31, 2019</study_first_submitted>
  <study_first_submitted_qc>March 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kocaeli University</investigator_affiliation>
    <investigator_full_name>Şener Gezer</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Sentinel Lymph Node</keyword>
  <keyword>Paraaortic nodes involvement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

